Endocrine Abstracts

Objectives: i) To determine the prevalence of major comorbidities of morbid obese, ii) to evaluate the gastric bypass effect on this comorbidities, on the 10 years estimated cardiovascular risk and iii) To assess the impact of bariatric surgery on the quality of life in these patients.

Methods: Cohort study with intrasubject measures (before–after) in a sample of patients with morbid obesity who underwent gastric bypass. Demographic characteristics, anthropometric parameters, cardiovascular risk factors and surgical complications were analyzed. The estimation of cardiovascular disease risk at 10 years was determined according to the Framingham Risk Score and the impact on the quality of life using the BAROS test (Bariatric Analysis and Reporting Outcome System).

Results: 162 patients were included (74.3% females), with mean age 38.87±10.11 years and BMI before surgery 51.12±7.22 kg/m². Two years after surgery the percentage of weight lost was 72.85%. Four months after the bypass only 12 of the 41 patients with type 2 diabetes maintained the diagnosis of diabetes. Two years after surgery, the resolution of hypertension, dyslipidemia and diabetes occurred in 71.93, 92.7, and 92.68% cases respectively (P<0.001). According to the Framingham Risk Score, 22.7% presented with a risk greater than 10% before surgery. Mean risk decreased from 5.82% at baseline to 2.21% 2 years after surgery (P<0.001). 14.9% of patients had early complications and 27.2% developed later complications (the most frequent eventration). BAROS scale was excellent in 36.8% of cases, very good in 36.7% and good in 21.1% at 2 years.

Conclusions: Gastric bypass is an effective tool in weight loss, early beneficial effects on metabolic disorders, reduction in cardiovascular risk and improvement quality of life in morbid obese patients in our area.